Evommune (EVMN) Accumulated Expenses (2024 - 2026)

Evommune (EVMN) has 3 years of Accumulated Expenses data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Accumulated Expenses changed N/A year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (changed N/A YoY) and the FY2025 annual result came in at $9.5 million, up 41.88% from the prior year.
• Accumulated Expenses slipped to $1.3 million in Q1 2026 per EVMN's latest filing, from $9.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $9.5 million in Q4 2025 and bottomed at $1.3 million in Q1 2026.
• The 3-year median for Accumulated Expenses is $6.5 million (2024), against an average of $6.0 million.
• Peak annual rise in Accumulated Expenses reached 41.88% in 2025, while the deepest fall reached 41.88% in 2025.
• Tracing EVMN's Accumulated Expenses over 3 years: stood at $6.7 million in 2024, then soared by 41.88% to $9.5 million in 2025, then slumped by 86.44% to $1.3 million in 2026.
• Per Business Quant, the three latest EVMN Accumulated Expenses figures stand at $1.3 million (Q1 2026), $9.5 million (Q4 2025), and $6.3 million (Q3 2025).

Peer Comparison